The effects of Roflumilast on the chemotactic capacity of leukocytes from COPD patients

Trial Profile

The effects of Roflumilast on the chemotactic capacity of leukocytes from COPD patients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2016

At a glance

  • Drugs Roflumilast (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics
  • Most Recent Events

    • 21 Jul 2016 Planned initiation date changed from 1 Aug 2016 to 1 Dec 2015.
    • 21 Jun 2016 Planned initiation date changed from 1 Dec 2015 to 1 Aug 2016.
    • 28 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top